Tianjin Development Posts 77% Profit Jump for 2023

Tianjin Development Holdings' (HKG:0882) attributable profit surged to nearly HK$635.6 million for the year ended December 2023, as compared to HK$358.2 million in the previous year, according to a Th

MT NewswiresApr 26 19:33

Tianjin Development (00882.HK): Lisheng Pharmaceuticals' net profit of 59,155,600 yuan in the first quarter increased 27.22% year-on-year

Gelonghui, April 25 | Tianjin Development (00882.HK) announced that in the first quarter of 2024, Lisheng Pharmaceutical (002393.SZ) achieved operating income of 365 million yuan, up 8.71% year on year; net profit attributable to shareholders of listed companies (Lisheng Pharmaceutical) was 59,1556 million yuan, up 27.22% year on year; net profit attributable to shareholders of listed companies (Lisheng Pharmaceuticals) after deducting non-recurring profit and loss was 58.7736 million yuan, up 29.71% year on year; basic earnings per share were 0.32 yuan.

Gelonghui FinanceApr 25 06:22

天津發展：天津力生製藥股份有限公司截至二零二四年三月三十一日止三個月之未經審核財務業績

Futu NewsApr 25 06:15 · Announcements

天津發展：二零二三年年報

Futu NewsApr 25 06:07 · Announcements

TIANJIN DEV To Go Ex-Dividend On June 20th, 2024 With 0.088 HKD Dividend Per Share

March 28th - $TIANJIN DEV(00882.HK)$ is trading ex-dividend on June 20th, 2024. Shareholders of record on June 21st, 2024 will receive 0.088 HKD dividend per share on July 29th, 2024. The ex-divid

Futu NewsMar 28 17:10

Tianjin Development (00882): Central Pharmaceutical, a wholly-owned subsidiary of Lisheng Pharmaceuticals, received a civil ruling

Tianjin Development (00882) issued an announcement. Recently, Tianjin Lisheng Pharmaceutical Co., Ltd., a non-wholly-owned subsidiary of the company...

Zhitong FinanceMar 28 06:31